文献速递甲状腺疾病糖尿病肥胖与代谢综合征

GLP-1受体激动剂启动后左甲状腺素治疗患者的TSH检测模式:一项试验模拟研究

Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性队列研究模拟目标试验,利用2011至2020年美国Medicare数据,比较2型糖尿病老年患者启动GLP-1 RA与SGLT-2i后TSH检测模式。倾向评分1:1匹配5370例患者,两组1年内约83.0%接受TSH检测,平均检测时间约130.5天,无显著差异。提示尽管GLP-1 RA减重可能需调整左甲状腺素剂量,但TSH监测模式未改变。

要点

  • GLP-1 RA与SGLT-2i启动后TSH检测率及时间无差异
  • 两组1年内TSH检测率约83.0%,平均检测时间约130.5天
  • GLP-1 RA减重可能需调整左甲状腺素剂量,但监测未跟上

核心结论

  • GLP-1 RA与SGLT-2i启动后TSH检测模式无差异,尽管GLP-1 RA减重更可能需调整左甲状腺素剂量。

研究设计与样本

  • 回顾性队列研究模拟目标试验,采用意向性治疗分析,倾向评分1:1匹配。
  • 研究对象为年龄≥65岁、基线左甲状腺素剂量稳定且患2型糖尿病的成人。
  • 比较启动GLP-1 RA与启动/持续使用SGLT-2i的患者。

主要发现

  • 共匹配5370例患者,平均年龄73.2岁,71.6%为女性,87.1%为白人。
  • 两组约83.0%的患者在1年随访内接受TSH检测。
  • 两组平均TSH检测时间均约为130.5天。

临床怎么用

  • GLP-1 RA治疗减重可能降低左甲状腺素需求,临床应加强体重变化后的甲状腺功能监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for type 2 diabetes and obesity and can lead to substantial weight loss. In patients taking levothyroxine, weight loss can reduce thyroid hormone requirements and potentially associated adverse effects. Thyroid-stimulating hormone (TSH) monitoring is essential but unclear whether thyroid function is routinely reassessed after GLP-1 RAs initiation. OBJECTIVE: Examine the changes in the timing of TSH testing after GLP-1 RAs. DESIGN: Retrospective cohort study emulating a target trial using Medicare from January 1, 2011, to December 31, 2020. The primary analysis followed an intention-to-treat approach. Patients were matched 1:1 using propensity scores. Logistic regression models and informed by least absolute shrinkage operator variable selection were used. SETTING: The 15% sample of U.S. Medicare fee-for-service claims data. PATIENTS OR OTHER PARTICIPANTS: Adults aged ≥65 years with type 2 diabetes on a stable levothyroxine dose at baseline. INTERVENTION(S): Initiation of GLP-1 RAs vs initiation/ongoing use of sodium-glucose cotransporter-2 inhibitors (SGLT-2is). MAIN OUTCOME MEASURE(S): TSH testing during follow-up. RESULTS: Among 5370 matched patients, the mean age was 73.2 years. 71.6% were women, and 87.1% were White. Approximately 83.0% of patients in both treatment groups receive a TSH testing within a 1-year follow-up. The mean time to TSH testing was approximately 130.5 days for both groups. CONCLUSION: TSH testing patterns did not differ between GLP-1 RAs and SGLT-2is, despite the greater likelihood of requiring levothyroxine dose adjustment associated with weight loss seen with GLP-1 RA therapy. Given levothyroxine's widespread use, this gap suggests missed opportunities for timely and weight-responsive thyroid monitoring.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Chen Y, Du F, Singh Ospina NM, et al. Patterns of TSH test after GLP-1 RAs initiation in patients on levothyroxine: a trial emulation study. J Clin Endocrinol Metab. 2026. PMID: 41902399. doi:10.1210/clinem/dgag131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。